Form 4: DSS, Inc. Reports Sale of Impact Biomedical Inc. Shares

DSS, Inc. reports the sale of 890,800 shares of Impact Biomedical Inc. common stock on April 4, 2025.

Summary

• DSS, Inc. filed a Form 4 detailing changes in beneficial ownership of Impact Biomedical Inc. stock.
• On April 4, 2025, DSS, Inc. sold 890,800 shares of common stock at a price of $0.9486 per share.
• Following the transaction, DSS, Inc. directly owns 161,100 shares of Impact Biomedical Inc. common stock.
• DSS, Inc. also indirectly owns 1,178,882 shares through its wholly-owned subsidiary, DSS BioHealth Security, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing reporting a stock sale. It doesn't inherently convey positive or negative sentiment, but the sale of shares by a major shareholder could be interpreted neutrally to slightly negatively depending on the context.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and major shareholders.

Stakeholder Impact

• The sale of shares by DSS, Inc. could potentially impact the share price of Impact Biomedical Inc.
• Shareholders may react to the news of the sale, depending on their perception of DSS, Inc.'s motives.

Key Dates

Keywords

Form 4, beneficial ownership, Impact Biomedical Inc., DSS, Inc., stock sale, IBO